Stay updated on CBDV Safety & Tolerability in ASD Clinical Trial
Sign up to get notified when there's something new on the CBDV Safety & Tolerability in ASD Clinical Trial page.

Latest updates to the CBDV Safety & Tolerability in ASD Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe clinical trial record for a Phase 2 study of cannabidivarin (CBDV) for children and young adults with autism spectrum disorder is displayed, including its termination after enrolling one participant and detailed study information.SummaryDifference43%

- Check15 days agoChange DetectedThe site footer revision changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check22 days agoChange DetectedAn NIH-wide banner announces a transition from the term “Artificial Intelligence” to “Super Intelligence” across NIH content.SummaryDifference1%

- Check28 days agoChange DetectedThe footer’s site revision label changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check35 days agoChange DetectedThe footer revision label was updated from v3.7.0 to v3.7.1 on the error page.SummaryDifference0.2%

- Check49 days agoChange DetectedThe study page now shows a 403 Forbidden error instead of the expected content, indicating access to the page is blocked. The header includes a Home link, signaling a path back to the site root.SummaryDifference0.5%

Stay in the know with updates to CBDV Safety & Tolerability in ASD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CBDV Safety & Tolerability in ASD Clinical Trial page.